XFOR
X4 Pharmaceuticals, Inc
NASDAQ · Healthcare · Biotechnology · US
$3.35
−0.30%Year over year
Reported trailing growth
- Revenue
- -51.6%
- EBITDA
- +12.4%
- EBIT
- +17.0%
- EPS
- +91.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -32.3%
- EBITDA
- -4.0%
- EPS
- +37.2%
Three-year CAGR
- Revenue
- +1273.2%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- +66.5%
- Free cash flow
- +35.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026